

Friday 17 April–Saturday 18 April 2015

Renaissance Barcelona Fira Hotel, Barcelona, Spain

Friday 17 April 2015

Session :Emerging Therapies in rheumatoid arthritis

09:00 – 12:00

J Gómez-Reino (Spain)

A Gül (Turkey)

Chairs and moderators:**Session: Inflammatory disorders: The 21st century treatment paradigm**

13:30–13:45

Welcome and introduction

J Gómez-Reino (Spain)

13:45–14:05

Inflammatory disorders this millennia – just how far have we come?

J Smolen (Austria)

14:05–14:30

Inflammatory disorders – pathways and potential treatment targets for the future

A Gül (Turkey)

14:30–14:40

Q&A

J Smolen (Austria)

A Gül (Turkey)

14:40–15:25

Open issues in inflammatory disorders – a regional perspective

Moderator: R Strohal (Austria)*Presentations:*

N Akkoç (Turkey)

N Wikonkál (Hungary)

Expert Panel:

D Karateev (Russia)

C Codreanu (Romania)

A Karamova (Russia) *TBC*

AD Cohen (Israel)

15:25–15:30

Session wrap up/Chair commentary

J Smolen (Austria)

15:30–16:00

Coffee break and poster viewing

Breakout sessions

16:00–18:00

New treatments in rheumatoid arthritis and psoriasis**Clinical case discussions: Learning from experience**

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Clinical roundtable discussion and case studies (invitation only)

Clinical roundtable discussions with case studies (approved biologics)

Moderator:
D Karateev (Russia)Moderator:
O Elkayam (Israel)Moderator:
A Karamova (Russia)
*TBC*Moderator:
H Amital
(Israel)Moderator:
A Nicolescu
(Romania)Moderator:
EJ Kucharz
(Poland)I Ertenli
(Turkey) *TBC*

Lifecycle of JAK inhibitors

Infections S Pay (Turkey)

JAK/STAT inhibitors: Impact of MoA on clinical outcomes

Paradoxical side effects of biologics S Segart (Belgium)

A Gül (Turkey) / H Bachelez (France) *TBC*

Differentiation between skin diseases N Wikonkál (Hungary)

Efficacy and clinical
experience
D Kyburz
(Switzerland)Efficacy and clinical
experience
*TBC*Current treatment
landscape in
psoriasis: A regional
perspective
AD Cohen (Israel)Biologics in special circumstances: Pregnancy, surgery, amyloidosis
I Ancuta (Romania) / J Vencovský (Czech Republic)

T2T in PsA patient R Olteanu (Romania) / T Korotaeva (Russia)

Safety
A Balanescu
(Romania)Safety
A Gül (Turkey)JAK/STAT inhibitors:
A future treatment
option for PSO?
H Bachelez (France)

6TH INFLAMMATION FORUM

INFORM

Friday 17 April–Saturday 18 April 2015

Renaissance Barcelona Fira Hotel, Barcelona, Spain

Saturday 18 April 2015

Time	Topic	Presenters
Session: Inflammatory disorders: Current treatment practices		Chairs and moderators: A Balsa (Spain), R Strohal (Austria)
08:30–08:40	Welcome and introduction	A Balsa (Spain)
08:40–09:20	Evolution of clinical targets to achieve comprehensive patient goals – a rheumatologist and dermatologist perspective	R Moots (UK) <i>Rheumatology</i> R Strohal (Austria) <i>Dermatology</i>
09:20–09:40	Immunogenicity – considerations for clinical practice	A Balsa (Spain)
09:40–10:00	Treatment targets – current opinions	A Balsa (Spain) R Moots (UK) J Gómez-Reino (Spain) R Strohal (Austria) O Elkayam (Israel) J Smolen (Austria)
10:00–10:30	Coffee break and poster viewing	
Rheumatology parallel session		Moderator: C Codreanu (Romania)
10:30–10:35	Welcome and introduction	C Codreanu (Romania)
10:35–10:55	The changing biosimilar landscape: An update	T Dörner (Germany)
10:55–11:25	Optimising therapy: Practicalities for the clinic	EJ Kucharz (Poland) D Opris (Romania) S Szántó (Hungary)
11:25–12:00	What do national registries tell us?	<i>Presentation:</i> EJ Kucharz <i>Expert Panel:</i> S Rednic (Romania) D Karateev (Russia) N Akkoç (Turkey) J Vencovský (Czech Republic) H Amital (Israel)
Dermatology parallel session		Moderator: A Nicolescu (Romania)
10:30–10:35	Welcome and introduction	A Nicolescu (Romania)
10:35–10:55	Optimising therapy: Practicalities for the clinic	N Wikonkál (Hungary) <i>TBC</i> R Strohal (Austria)
10:55–11:25	What do national registries tell us?	<i>Presentation:</i> AD Cohen (Israel) <i>TBC</i> <i>Expert Panel:</i> AD Cohen (Israel) A Karamova (Russia) <i>TBC</i> A Nicolescu (Romania) N Wikonkál (Hungary)
11:25–12:00	The changing biosimilar landscape: An update and dermatological perspective	T Dörner (Germany) AD Cohen (Israel)
Session: Inflammatory disorders: Enhancing patient care		Chair and moderator: I Ertenli (Turkey)
12:00–12:25	Enhancing patient experience: Thinking outside of the toolbox!	S Rednic (Romania) O Elkayam (Israel)
12:25–12:50	Strategies to improve patient outcomes	N Akkoç (Turkey) H Amital (Israel)
12:50–13:20	Expertepilogue: Mytreatmentmilestone	A Gül (Turkey) A Balsa (Spain) <i>TBC</i> R Strohal (Austria) <i>TBC</i> S Segaeert (Belgium)
13:20–13:30	Summary and close	I Ertenli (Turkey)